source
- Amgen’s Repatha linked to fewer heart attacks while Novartis reports seven new tumor cases in Zolgensma patientsAmgen reported that its cholesterol‑lowering drug Repatha was associated with a lower incidence of heart attacks in a recent analysis. The data suggest the therapy may provide cardiovascular benefi…
- Regulators urge risk-based lifecycle approach for AI tools amid election-linked FDA uncertaintyA panel of regulatory experts at the RAPS AI in Regulatory Conference in Barcelona urged professionals using AI tools to adopt a risk-based, life-cycle perspective rather than focusing solely on va…